SRX-3177

N/A

Report date: 2021/12/07 16:26:23
NME

Base Information

Drug NameSRX-3177
Drug Alias NameSRX-3177
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 4 inhibitorsCyclin-dependent kinase 6 inhibitorsPhosphatidylinositol 3 kinase alpha inhibitors +[4] 
TargetsCyclin-dependent kinase 4Cyclin-dependent kinase 6Phosphatidylinositol 3 kinase alpha +[4] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSignalrx Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSignalrx Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A